DB Wealth Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

DB Wealth Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$36.2K	Hold	89	–	–	0.02%	186
2023 Q3	$30.9K	Hold	89	–	–	0.02%	188
2023 Q2	$31.3K	Hold	89	–	–	0.02%	185
2023 Q1	$28K	Hold	89	–	–	0.02%	196
2022 Q4	$25.7K	Hold	89	–	–	0.02%	202
2022 Q3	$26K	Hold	89	–	–	0.02%	209
2022 Q2	$25K	Hold	89	–	–	0.02%	212
2022 Q1	$23K	Buy	+89	New	+$21.1K	0.01%	246

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DB Wealth Management Group's VRTX Position: Q4 2023 in Review

DB Wealth Management Group held its Vertex Pharmaceuticals (VRTX) position steady in Q4 2023 at 89 shares worth $36.2K. The position accounts for 0.02% of the portfolio, ranked #186.

DB Wealth Management Group first reported a position in VRTX in Q1 2022 and has held it in 8 quarters since. 1,438 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

DB Wealth Management Group held 89 shares of Vertex Pharmaceuticals worth $36.2K as of Q4 2023.
DB Wealth Management Group left its Vertex Pharmaceuticals share count unchanged in Q4 2023.
Vertex Pharmaceuticals made up 0.02% of DB Wealth Management Group's portfolio in Q4 2023, its #186 holding.
DB Wealth Management Group first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
1,438 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on DB Wealth Management Group's 13F filing for Q4 2023, filed 9 Jan 2024.